Octagon Capital Advisors
Octagon Capital Advisors reported 25 stocks worth $740M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are DNTH (20.1%), ABVX (13.3%) and DFTX (12.9%). Compared with Q2 2026, the fund opened new positions in OBX and TNGX, added to AVBP, trimmed DNTH, DFTX and KYMR and sold out of ALMS, SMMT and CNTX.
Latest filing: what Octagon Capital Advisors did in Q3 2026
vs Q2 2026
AVBP+$5.2M+9%
Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() DNTH Dianthus Therapeutics Inc | $149M | 20.1% | 1.7M | −155K (−8%) | 8 of 8 | |
| 2 | ![]() ABVX Abivax SA | $98.3M | 13.3% | 993K | No change | 7 of 8 | |
| 3 | ![]() DFTX Definium Therapeutics Inc | $95.6M | 12.9% | 2.5M | −439K (−15%) | 3 of 8 | |
| 4 | ![]() COGT Cogent Biosciences Inc | $75.2M | 10.2% | 2.4M | No change | 8 of 8 | |
| 5 | ![]() AVBP Arrivent Biopharma Inc | $64.8M | 8.8% | 2.1M | +170K (+9%) | 8 of 8 | |
| 6 | ![]() TSHA Taysha Gene Therapies Inc | $47.2M | 6.4% | 9.7M | No change | 8 of 8 | |
| 7 | ![]() OBX Obsidian Therapeutics Inc | $33.2M | 4.5% | 2.4M | New position | 1 of 8 | |
| 8 | ![]() KYMR Kymera Therapeutics Inc | $22.9M | 3.1% | 205K | −105K (−34%) | 6 of 8 | |
| 9 | ![]() IRON Disc Medicine Inc | $17.7M | 2.4% | 270K | No change | 3 of 8 | |
| 10 | ![]() TNGX Tango Therapeutics Inc | $15.7M | 2.1% | 630K | New position | 1 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
![]() ERAS Erasca Inc | Call | $10.6M | 720K | −535,000 |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Octagon Capital Advisors 13F FAQ
What does Octagon Capital Advisors own?
Octagon Capital Advisors reported 25 stocks worth $740M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are DNTH (20.1%), ABVX (13.3%) and DFTX (12.9%). The table above lists every position in the filing (the top 10 without an account).
What did Octagon Capital Advisors buy and sell in Q3 2026?
Compared with Q2 2026: 2 new positions, 1 added to, 13 trimmed and 3 sold out. New positions include OBX and TNGX. It sold all of ALMS, SMMT and CNTX.
When will Octagon Capital Advisors file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Octagon Capital Advisors's portfolio worth?
The Q3 2026 filing reports $740M in US stocks ($751M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.














